Immuron Ltd（IMRN）のニュースとイベントIMRNImmuron Ltd

Trump Administration Injects $150M into xLight

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.XLIGHT STAKE:The Trump administration has agreed to inject up to $150M into xLight, which makes lasers for EUV machines and has former IntelCEO Pat Gelsinger on its board, for an equity stake, The Wall Street Journal's Amrith Ramkumar and Robbie Whelan. ASMLis currently the only global producer of EUV machines, which can cost hundreds of millions of dollars each.AMICABLE SETTLEMENT:Trump Media and Technologyannounced that Trump Media and United Atlantic Ventures reached an "amicable" settlement of their dispute and all claims by Trump Media against United Atlantic Ventures have been mutually resolved.NEW DOD AWARD:Immuronannounced a new research agreement with the Naval Medical Research Command -NMRC - and the Walter Reed Army Institute of Research, or WRAIR, Silver Spring, MD, USA funded by a U.S. Department of Defense subaward.The Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting Campylobacter jejuni and Shigella sonnei. Under a recently executed collaborative research agreement with the Henry M. Jackson Foundation, new vaccine preparations against these pathogens have been developed and formulated at the military research institutes and subsequently provided to Immuron.Immuron will produce two hyper-immune bovine colostrum products for pre-clinical evaluation, with the objective of advancing a combined colostrum-based therapeutic specifically designed for the U.S. military. Also, the Uniformed Services University topline results from its clinical trial evaluating the effectiveness of enterotoxigenic E. coli hyperimmune bovine colostrum in maintaining gut health during deployment and travel are anticipated to be announced at the end of next week. In P2TD study, IMM-124E - the active ingredient in Travelan - was delivered in 600 mg powder sachets and administered twice daily in a randomized, placebo-controlled trial.Infectious diarrhea is the most common illness reported by travelers visiting developing countries and among U.S. troops deployed overseas. In the last decade, several enteric pathogens have an increasing resistance to commonly prescribed antibiotics.

Immuron Signs New Research Agreement with Naval Medical Research Command

Immuron announced a new research agreement with the Naval Medical Research Command - NMRC - and the Walter Reed Army Institute of Research, or WRAIR, Silver Spring, MD, USA funded by a U.S. Department of Defense subaward.The Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting Campylobacter jejuni and Shigella sonnei. Under a recently executed collaborative research agreement with the Henry M. Jackson Foundation, new vaccine preparations against these pathogens have been developed and formulated at the military research institutes and subsequently provided to Immuron. Immuron will produce two hyper-immune bovine colostrum products for pre-clinical evaluation, with the objective of advancing a combined colostrum-based therapeutic specifically designed for the US military. Also, the Uniformed Services University topline results from its clinical trial evaluating the effectiveness of enterotoxigenic E. coli hyperimmune bovine colostrum in maintaining gut health during deployment and travel are anticipated to be announced at the end of next week. In P2TD study, IMM-124E - the active ingredient in Travelan - was delivered in 600 mg powder sachets and administered twice daily in a randomized, placebo-controlled trial. Infectious diarrhea is the most common illness reported by travelers visiting developing countries and among US troops deployed overseas. In the last decade, several enteric pathogens have an increasing resistance to commonly prescribed antibiotics.

Immuron Receives FDA Approval for IND of IMM-529

Immuron is pleased to announce that the United States FDA has approved Immuron's Investigational New Drug application for IMM-529 and the Phase 2 clinical trial may proceed. The company plans to initiate a Phase 2 clinical trial for IMM-529 in individuals with Clostridioides difficile infection during the first half of 2026.